Cargando…
Targeted Therapy for Melanomas Without BRAF V600 Mutations
Modern therapy of advanced melanoma offers effective targeted therapeutic options in the form of BRAF plus MEK inhibition for patients with BRAF V600 mutations. For patients lacking these mutations, checkpoint inhibition remains the only first-line choice for treatment of metastatic disease. However...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042969/ https://www.ncbi.nlm.nih.gov/pubmed/35380338 http://dx.doi.org/10.1007/s11864-022-00946-4 |